A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium StudyHirva Mamdani, Shadia I. Jalal, Bryan J. Schneider et al.|Frontiers in Oncology|2021Cited by 40
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.Hirva Mamdani, Shadia I. Jalal, Heather Burney et al.|Journal of Clinical Oncology|2019Cited by 10
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from Big Ten Cancer Research Consortium study.Hirva Mamdani, Shadia I. Jalal, Bryan J. Schneider et al.|Journal of Clinical Oncology|2019Cited by 5
Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study.Hirva Mamdani, Shadia I. Jalal, Bryan J. Schneider et al.|Journal of Clinical Oncology|2020Cited by 5
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Two-year follow-up results from Big Ten Cancer Research Consortium study.Hirva Mamdani, Shadia I. Jalal, Bryan J. Schneider et al.|Journal of Clinical Oncology|2020Cited by 4